http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 17:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Dewhurst+Martin+William/26618496.html si-local-file:///var/storage/secattach/20260608/26618496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Dewhurst+Martin+William/26618496.html Mon, 08 Jun 2026 17:32:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Kester+Kent+Edward/26618484.html si-local-file:///var/storage/secattach/20260608/26618484.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Kester+Kent+Edward/26618484.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+GOLDEN+ARTHUR+F/26618491.html si-local-file:///var/storage/secattach/20260608/26618491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+GOLDEN+ARTHUR+F/26618491.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Gengos+Andrew/26618492.html si-local-file:///var/storage/secattach/20260608/26618492.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Gengos+Andrew/26618492.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+03/26594956.html si-local-file:///var/storage/secattach/20260603/26594956.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+03/26594956.html Wed, 03 Jun 2026 06:13:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+May+28++Filed+by%3A+BEB+Holdings%2C+LLC/26585417.html si-local-file:///var/storage/secattach/20260601/26585417.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+May+28++Filed+by%3A+BEB+Holdings%2C+LLC/26585417.html Mon, 01 Jun 2026 18:07:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+01/26580057.html si-local-file:///var/storage/secattach/20260601/26580057.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+01/26580057.html Mon, 01 Jun 2026 08:45:00 -0400 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) announced interim analysis results from its Phase 2 trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. The analysis included the first 50 completed subjects in the randomized, double-blind, vehicle-controlled study.</p> <p>In the interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks compared to 65.2% for vehicle-treated subjects. At the four-week mark, 44.4% of GX-03 patients achieved a 90% reduction in severity versus 30.4% for vehicle. By week eight, 51.9% of GX-03 patients reached 90% reduction compared to 34.8% for vehicle.</p> <p>The company reported no treatment-related serious adverse http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html Mon, 01 Jun 2026 08:30:17 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) announced interim analysis results from its Phase 2 trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. The analysis included the first 50 completed subjects in the randomized, double-blind, vehicle-controlled study.</p> <p>In the interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks compared to 65.2% for vehicle-treated subjects. At the four-week mark, 44.4% of GX-03 patients achieved a 90% reduction in severity versus 30.4% for vehicle. By week eight, 51.9% of GX-03 patients reached 90% reduction compared to 34.8% for vehicle.</p> <p>The company reported no treatment-related serious adverse http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html Mon, 01 Jun 2026 08:30:17 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) announced interim analysis results from its Phase 2 trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. The analysis included the first 50 completed subjects in the randomized, double-blind, vehicle-controlled study.</p> <p>In the interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks compared to 65.2% for vehicle-treated subjects. At the four-week mark, 44.4% of GX-03 patients achieved a 90% reduction in severity versus 30.4% for vehicle. By week eight, 51.9% of GX-03 patients reached 90% reduction compared to 34.8% for vehicle.</p> <p>The company reported no treatment-related serious adverse http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html Mon, 01 Jun 2026 08:30:17 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) announced interim analysis results from its Phase 2 trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. The analysis included the first 50 completed subjects in the randomized, double-blind, vehicle-controlled study.</p> <p>In the interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks compared to 65.2% for vehicle-treated subjects. At the four-week mark, 44.4% of GX-03 patients achieved a 90% reduction in severity versus 30.4% for vehicle. By week eight, 51.9% of GX-03 patients reached 90% reduction compared to 34.8% for vehicle.</p> <p>The company reported no treatment-related serious adverse http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html Mon, 01 Jun 2026 08:30:17 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) announced interim analysis results from its Phase 2 trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. The analysis included the first 50 completed subjects in the randomized, double-blind, vehicle-controlled study.</p> <p>In the interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks compared to 65.2% for vehicle-treated subjects. At the four-week mark, 44.4% of GX-03 patients achieved a 90% reduction in severity versus 30.4% for vehicle. By week eight, 51.9% of GX-03 patients reached 90% reduction compared to 34.8% for vehicle.</p> <p>The company reported no treatment-related serious adverse http://www.streetinsider.com/FDA/Turn+Therapeutics+reports+positive+interim+data+from+atopic+dermatitis+trial/26579837.html Mon, 01 Jun 2026 08:30:17 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html <p class="bwalignc"> 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) </p><p class="bwalignc"> Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy </p><p class="bwalignc"> No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period </p> <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Reports+Interim+Analysis+Findings+and+Adaptive+Optimization+Strategy+from+Phase+2+GX-03+Trial+in+Moderate-to-Severe+Atopic+Dermatitis/26579810.html Mon, 01 Jun 2026 08:30:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+May+27/26553945.html si-local-file:///var/storage/secattach/20260527/26553945.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+May+27/26553945.html Wed, 27 May 2026 08:11:00 -0400 TTRX http://www.streetinsider.com/Corporate+News/Turn+Therapeutics+publishes+study+showing+GX-03+reduces+skin+inflammation/26553906.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) published a peer-reviewed study in the Journal of Dermatological Treatment demonstrating its experimental drug GX-03 reduced disease severity in a mouse model of dermatitis.</p><p>The study evaluated GX-03 in mice with Staphylococcus aureus-induced dermatitis characterized by IL-36 expression, a cytokine associated with skin inflammation. Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 compared to 3.00 in untreated controls, representing a statistically significant reduction in disease severity.</p><p>The research was co-authored by Bradley Burnam, Turn Therapeutics' chief executive officer, and Stephen Bresnick, a physician and company advisor. The http://www.streetinsider.com/Corporate+News/Turn+Therapeutics+publishes+study+showing+GX-03+reduces+skin+inflammation/26553906.html Wed, 27 May 2026 08:05:36 -0400 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+publishes+study+showing+GX-03+reduces+skin+inflammation/26553906.html <p>Turn Therapeutics Inc. (NASDAQ: TTRX) published a peer-reviewed study in the Journal of Dermatological Treatment demonstrating its experimental drug GX-03 reduced disease severity in a mouse model of dermatitis.</p><p>The study evaluated GX-03 in mice with Staphylococcus aureus-induced dermatitis characterized by IL-36 expression, a cytokine associated with skin inflammation. Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 compared to 3.00 in untreated controls, representing a statistically significant reduction in disease severity.</p><p>The research was co-authored by Bradley Burnam, Turn Therapeutics' chief executive officer, and Stephen Bresnick, a physician and company advisor. The http://www.streetinsider.com/FDA/Turn+Therapeutics+publishes+study+showing+GX-03+reduces+skin+inflammation/26553906.html Wed, 27 May 2026 08:05:36 -0400 TTRX